BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, Matucci-Cerinic M, Allanore Y. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum 2016;46:115-23. [PMID: 27132536 DOI: 10.1016/j.semarthrit.2016.02.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, Matucci-Cerinic M, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Riccieri V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology (Oxford) 2018;57:441-50. [PMID: 28499034 DOI: 10.1093/rheumatology/kex182] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
2 Becker MO, Dobrota R, Garaiman A, Debelak R, Fligelstone K, Tyrrell Kennedy A, Roennow A, Allanore Y, Carreira PE, Czirják L, Denton CP, Hesselstrand R, Sandqvist G, Kowal-Bielecka O, Bruni C, Matucci-Cerinic M, Mihai C, Gheorghiu AM, Mueller-Ladner U, Sexton J, Kvien TK, Heiberg T, Distler O. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Ann Rheum Dis 2021:annrheumdis-2021-220702. [PMID: 34824049 DOI: 10.1136/annrheumdis-2021-220702] [Reference Citation Analysis]
3 Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open 2018;4:e000782. [PMID: 30402270 DOI: 10.1136/rmdopen-2018-000782] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
4 Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D. The patient experience of Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford) 2019;58:18-26. [PMID: 29538754 DOI: 10.1093/rheumatology/key026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
5 Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respir Res 2020;7:e000598. [PMID: 32576559 DOI: 10.1136/bmjresp-2020-000598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Stöcker JK, Vonk MC, van den Hoogen FHJ, Nijhuis-van der Sanden MWG, Spierings J, Staal JB, Satink T, van den Ende CHM; ARCH study group. Room for improvement in non-pharmacological systemic sclerosis care? - a cross-sectional online survey of 650 patients. BMC Rheumatol 2020;4:43. [PMID: 32760879 DOI: 10.1186/s41927-020-00142-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 van Leeuwen NM, Ciaffi J, Liem SIE, Huizinga TWJ, de Vries-Bouwstra JK. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford) 2021;60:3646-55. [PMID: 33401302 DOI: 10.1093/rheumatology/keaa827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Herrick AL. Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 2021;33:453-62. [PMID: 34420003 DOI: 10.1097/BOR.0000000000000826] [Reference Citation Analysis]
9 Lescoat A, Roofeh D, Townsend W, Hughes M, Sandler RD, Zimmermann F, Pauling JD, Buch MH, Khanna D. Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. BMJ Open 2021;11:e044765. [PMID: 33707273 DOI: 10.1136/bmjopen-2020-044765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hoffmann-Vold AM, Molberg Ø. Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. Curr Opin Rheumatol 2020;32:497-504. [PMID: 32890027 DOI: 10.1097/BOR.0000000000000741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Bratoiu I, Burlui A, Richter P, Cardoneanu A, Rezus C, Rezus E. Digestive Dysbiosis in Systemic Scleroderma: a Review. Journal of Interdisciplinary Medicine 2021;6:53-9. [DOI: 10.2478/jim-2021-0018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Galetti I, Nunzio SD, Brogelli L, Mirisola V, Garbagnati C. How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers. Curr Med Res Opin 2021;37:5-15. [PMID: 34726112 DOI: 10.1080/03007995.2021.1992371] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lescoat A, Murphy SL, Roofeh D, Pauling JD, Hughes M, Sandler R, Zimmermann F, Wessel R, Townsend W, Chung L, Denton CP, Merkel PA, Steen V, Allanore Y, Del Galdo F, Godard D, Cella D, Farrington S, Buch MH, Khanna D. Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. J Scleroderma Relat Disord 2021;6:66-76. [PMID: 34316516 DOI: 10.1177/2397198320961967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Allanore Y, Matucci-Cerinic M, Distler O. Treatment of systemic sclerosis: is there any hope for the future? RMD Open 2016;2:e000260. [PMID: 27486527 DOI: 10.1136/rmdopen-2016-000260] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 Stöcker JK, Vonk MC, van den Hoogen FHJ, Nijhuis-van der Sanden MWG, Spierings J, Staal JB, Satink T, van den Ende CHM; ARCH study group. Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. Rheumatol Int 2021;41:1299-310. [PMID: 33355711 DOI: 10.1007/s00296-020-04765-4] [Reference Citation Analysis]
16 Ciaffi J, van Leeuwen NM, Liem SI, Ninaber MK, Huizinga TW, de Vries-bouwstra JK. Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. Clin Rheumatol 2020;39:1543-9. [DOI: 10.1007/s10067-020-04951-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Allanore Y, Constans J, Godard D, de Pouvourville G, Bouee S, Jeanbat V, Teissier C, Le Lay K, Chollet J, Hachulla E. Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders 2022;7:49-56. [DOI: 10.1177/23971983211013979] [Reference Citation Analysis]
18 Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M;  Canadian Scleroderma Research Group (CSRG);  Australian Scleroderma Interest Group (ASIG); Baron M. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford). 2019;58:636-644. [PMID: 30517716 DOI: 10.1093/rheumatology/key350] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
19 Evers C, Jordan S, Maurer B, Becker MO, Mihai C, Dobrota R, Hoederath P, Distler O. Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis. Arthritis Res Ther 2021;23:34. [PMID: 33468227 DOI: 10.1186/s13075-021-02421-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019;38:3317-30. [PMID: 31420815 DOI: 10.1007/s10067-019-04745-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
21 Toprak U, Ozbalkan Z, Erdugan M, Parlak S, Sandıkcı SC, Kaya T, Şaylısoy S. Follow-Up of Treatment Response With Dynamic Doppler Ultrasound in Raynaud Phenomenon. AJR Am J Roentgenol 2017;209:W388-94. [PMID: 28981361 DOI: 10.2214/AJR.17.18143] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol 2017;69:1661-9. [PMID: 28426903 DOI: 10.1002/art.40123] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
23 Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Molberg Ø, Hoffmann-Vold AM. Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort. Rheumatology (Oxford) 2020;59:2920-9. [PMID: 32097470 DOI: 10.1093/rheumatology/keaa026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
24 Kocher A, Simon M, Dwyer AA, Villiger PM, Künzler-Heule P, De Geest S, Berben L, Nicca D. Developing a rare disease chronic care model: Management of systemic sclerosis (MANOSS) study protocol. J Adv Nurs 2019;75:3774-91. [PMID: 31452216 DOI: 10.1111/jan.14185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Costa-Pereira KR, Guimarães AL, Moraes DA, Dias JBE, Garcia JT, de Oliveira-Cardoso EA, Zombrilli A, Leopoldo V, Costa TM, Simões BP, Oliveira MC. Hematopoietic Stem Cell Transplantation Improves Functional Outcomes of Systemic Sclerosis Patients. J Clin Rheumatol 2020;26:S131-8. [PMID: 31397762 DOI: 10.1097/RHU.0000000000001117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
26 Preis E, Franz K, Siegert E, Makowka A, March C, Riemekasten G, Cereda E, Norman K. The impact of malnutrition on quality of life in patients with systemic sclerosis. Eur J Clin Nutr 2018;72:504-10. [DOI: 10.1038/s41430-018-0116-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
27 Zhang S, Lv J, Ren X, Hao X, Zhou P, Wang Y. The efficacy and safety of fecal microbiota transplantation in the treatment of systemic sclerosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e21267. [PMID: 32664182 DOI: 10.1097/MD.0000000000021267] [Reference Citation Analysis]
28 Allanore Y. Limited cutaneous systemic sclerosis: the unfairly neglected subset. Journal of Scleroderma and Related Disorders 2016;1:241-6. [DOI: 10.5301/jsrd.5000216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
29 Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, Wijsenbeek M, Kreuter M. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respir Res 2020;21:197. [PMID: 32703199 DOI: 10.1186/s12931-020-01459-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
30 Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D. Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. Arthritis Care Res (Hoboken) 2018;70:1653-60. [PMID: 29381834 DOI: 10.1002/acr.23522] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
31 Hoffmann-vold A, Fretheim H, Halse A, Seip M, Bitter H, Wallenius M, Garen T, Salberg A, Brunborg C, Midtvedt Ø, Lund MB, Aaløkken TM, Molberg Ø. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med 2019;200:1258-66. [DOI: 10.1164/rccm.201903-0486oc] [Cited by in Crossref: 55] [Cited by in F6Publishing: 22] [Article Influence: 18.3] [Reference Citation Analysis]
32 Khanna D, Allanore Y, Denton CP, Matucci-cerinic M, Pope J, Hinzmann B, Davies S, de Oliveira Pena J, Distler O. Patient perception of disease burden in diffuse cutaneous systemic sclerosis. Journal of Scleroderma and Related Disorders 2020;5:66-76. [DOI: 10.1177/2397198319866615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
33 Ngcozana T, Ong VH, Denton CP. Improving access to digital ulcer care through nurse-led clinic: a service evaluation. Musculoskeletal Care 2020;18:92-7. [PMID: 31961999 DOI: 10.1002/msc.1433] [Reference Citation Analysis]
34 Hoffmann-Vold AM, Fretheim HH, Sarna VK, Barua I, Carstens MN, Distler O, Khanna D, Volkmann ER, Midtvedt Ø, Didriksen H, Dhainaut A, Halse AK, Bakland G, Pesonen M, Olsen I, Molberg Ø. Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open 2021;11:e048541. [PMID: 34168032 DOI: 10.1136/bmjopen-2020-048541] [Reference Citation Analysis]
35 Kassamali B, Kus KJB, Mazori DR, Maher J, Lopez CG, Kassamali AA, Vleugels RA, LaChance AH. Race and gender differences in systemic sclerosis: a retrospective multicenter cohort. Int J Dermatol 2021. [PMID: 34510426 DOI: 10.1111/ijd.15908] [Reference Citation Analysis]
36 Hoffmann-vold A, Volkmann ER. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders 2021;6:37-43. [DOI: 10.1177/2397198319891282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
37 Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, Khanna D. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clin Rev Allergy Immunol 2021. [PMID: 34468946 DOI: 10.1007/s12016-021-08891-0] [Reference Citation Analysis]
38 Hoffmann-Vold AM, Distler O, Murray B, Kowal-Bielecka O, Khanna D, Allanore Y; EUSTAR and SCTC collaborators. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open 2019;5:e000826. [PMID: 30997150 DOI: 10.1136/rmdopen-2018-000826] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
39 Murphy SL, Barber M, Huang S, Sabbagh M, Cutter G, Khanna D. Intensive and App-Delivered Occupational Therapy to Improve Upper Extremity Function in Early Diffuse Cutaneous Systemic Sclerosis: A Pilot Two-Arm Trial. Rheumatology (Oxford) 2021:keab339. [PMID: 33839775 DOI: 10.1093/rheumatology/keab339] [Reference Citation Analysis]
40 Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Siegert E, Lazzaroni MG, Carreira PE, Vettori S, Zanatta E, Ullman S, Czirjàk L, Kowal-Bielecka O, Distler O, Matucci-Cerinic M, Allanore Y; EUSTAR co-authors. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmun Rev 2020;19:102452. [PMID: 31838157 DOI: 10.1016/j.autrev.2019.102452] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
41 Cüzdan N, Türk İ, Çiftçi V, Arslan D, Doğan MC, Ünal İ. The effect of a home-based orofacial exercise program on oral aperture of patients with systemic sclerosis: A single-blind prospective randomized controlled trial. Arch Rheumatol 2021;36:176-84. [PMID: 34527921 DOI: 10.46497/ArchRheumatol.2021.8295] [Reference Citation Analysis]
42 Sierakowska M, Sierakowski S, Sierakowska J, Krajewska-Kułak E, Ndosi M. Pain, fatigue and functional disability are associated with higher educational needs in systemic sclerosis: a cross-sectional study. Rheumatol Int 2018;38:1471-8. [PMID: 29497844 DOI: 10.1007/s00296-018-3998-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Allanore Y, Bozzi S, Terlinden A, Huscher D, Amand C, Soubrane C, Siegert E, Czirják L, Carreira PE, Hachulla E, Zanatta E, Li M, Airò P, Mendoza FA, Rosato E, Distler O; EUSTAR Collaborators. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Res Ther 2020;22:257. [PMID: 33115544 DOI: 10.1186/s13075-020-02329-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Huang W, Zhang L, Yan J. Psychometric evaluation of the Chinese version of the revised illness perception questionnaire for breast cancer-related lymphedema. Eur J Cancer Care (Engl) 2019;28:e12900. [PMID: 30144206 DOI: 10.1111/ecc.12900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Iudici M, Bafeta A, Atal I, Ravaud P. Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. Arthritis Care Res 2019;72:140-8. [DOI: 10.1002/acr.23817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Condon SE, Roesch SC, Clements PJ, Furst DE, Weisman MH, Malcarne VL. Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach. Journal of Scleroderma and Related Disorders 2020;5:231-6. [DOI: 10.1177/2397198320930138] [Reference Citation Analysis]
47 Yang H, Xu D, Li MT, Yao Y, Jin M, Zeng XF, Qian JM. Gastrointestinal manifestations on impaired quality of life in systemic sclerosis. J Dig Dis 2019;20:256-61. [PMID: 30838807 DOI: 10.1111/1751-2980.12720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]